Background
==========

Alzheimer's disease (AD), the most common form of irreversible dementia, is placing a considerable and increasing burden on patients, caregivers, and society, as more people live long enough to become affected \[[@b1-medscimonit-20-2250]\]. AD is clinically characterized by a progression from episodic memory problems to a slow global decline of cognitive function that leaves patients with end-stage AD bedridden and dependent on custodial care, with death occurring on average 9 years after diagnosis \[[@b2-medscimonit-20-2250]--[@b4-medscimonit-20-2250]\]. Studies have demonstrated that AD is a result of intricate interactions between interior and environmental factors, such as genetics, race, age, family history, obesity, and diet \[[@b5-medscimonit-20-2250]--[@b8-medscimonit-20-2250]\].

Ubiquilin 1 (UBQLN1) is an ubiquitin-like protein that has been shown to play a central role in regulating the proteasomal degradation of various proteins, including the presenilins (PSs). PS plays a fundamental role in AD pathogenesis \[[@b9-medscimonit-20-2250]\]. UBQLN1 has previously been shown to interact with PS1 and PS2; overexpression of UBQLN1 was reported to enhance the accumulation of PS holoproteins \[[@b10-medscimonit-20-2250],[@b11-medscimonit-20-2250]\]. More recently, down-regulation of UBQLN1 was reported to modulate PS1 endoproteolysis, along with protein levels of nicastrin and PEN-2 in non-neuronal cell lines \[[@b12-medscimonit-20-2250]\].

The *UBQLN1* gene on chromosome 9q22 lies in a region that has been implicated in several linkage studies of AD \[[@b13-medscimonit-20-2250]--[@b20-medscimonit-20-2250]\]. Several studies suggested that a single intronic C/T polymorphism, UBQ-8i (rs12344615), contributed to AD risk. This variant seemed to be less effective than the wild type due to variation in the central domain of ubiquilin. Ford et al. \[[@b21-medscimonit-20-2250]\] suggested that variations in the central part of the protein could facilitate its ability to form dimers, which in turn could be less capable of binding to PS1 than monomers. If ubiquilin does not bind to PS1, a gamma-secretase complex can form and become involved in the processing of the amyloid precursor protein. This entails the production of the peptides Aβ40 and Aβ42, which contribute to neurotoxicity. However, the previous results were inconsistent \[[@b13-medscimonit-20-2250]--[@b20-medscimonit-20-2250]\]. These disparate findings may be partly due to limited sample size, false-positive results, and publication bias. In the present study, a meta-analysis based on all published studies was performed to estimate the UBQ-8i polymorphism with AD susceptibility.

Material and Methods
====================

Identification and search of relevant studies
---------------------------------------------

To search for all the studies that examined the association of UBQ-8i with AD susceptibility, we conducted a comprehensive literature search of PubMed, EMBASE, Web of Science, CNKI (China Nation Knowledge Infrastructure Platform), CBM (China Biological Medicine Database), Wanfang, and VIP databases (up to May 2014), using the following MeSH terms and keywords: 'Ubiquilin 1', 'UBQLN1', 'UBQ-8i, 'polymorphism', 'Alzheimer's disease, 'Alzheimer disease or AD'. We also screened all the reference lists of retrieved articles and review articles and retrieved additional studies by hand-searching of relevant journals and by correspondence with authors of included studies. If there were multiple publications from the same study group, to prevent data duplication, the most complete and recent results were kept.

Eligible studies had to meet the following criteria: (a) only case-control studies were considered and (b) the study explored the correlation between AD and UBQ-8i. Major exclusion criteria were: (a) no control population, (b) no available genotype frequency, and (c) duplication of the previous publications (the largest or most recent publication was selected).

Data extraction
---------------

Information was extracted from all eligible publications independently by 2 authors according to the inclusion criteria listed above. The following information was extracted from each study: first author, publication year, racial background, age of patients, sex, number of cases and controls, adjustment, odds ratios (ORs), and the corresponding 95% confidence intervals (CIs) of AD risk.

Statistical analysis
--------------------

OR and 95% CI were applied to assess the strength of the association of UBQ-8i with AD. The dominant model (CT+CC *vs.* TT) was used in this meta-analysis, because most of the studies reported the results in this model. Heterogeneity among studies was calculated using the χ^2^-based Cochran's Q-statistic test (*P*\<0.10 was considered statistically significant heterogeneity), and the inconsistency index *I^2^* statistic was also calculated to observe between-study variability that was due to heterogeneity rather than chance. This statistic, which was documented by percentage, yields result ranging from 0% to 100% (*I^2^*=0--25%, no heterogeneity; *I^2^*=25--50%, moderate heterogeneity; *I^2^*=50--75%, large heterogeneity; *I^2^*=75--100%, extreme heterogeneity). A fixed-effects model using the Mantel and Haenszel method was used in the absence of between-study heterogeneity, and a random effects model using the method of DerSimonian and Laird was used to investigate variation both from in-study and between-study. Stratified analyses were performed in accordance with *APOE* ɛ4 status and age. We defined the early-onset AD (EOAD) as the first event before 70 years of age. Sensitivity analyses were conducted to estimate the stability of the results, such that each study was omitted one at a time to reflect the influence of the individual data set on the pooled OR. Cumulative meta-analysis was also conducted. Potential publication bias was assessed by visual inspection of funnel plot asymmetry, the Begg's rank correlation method, and the Egger's weighted regression method \[[@b22-medscimonit-20-2250]\]. All statistical analyses were conducted using STATA software version 11.0 and Revman 5.1. All *P* values were 2-sided.

Results
=======

Studies included in the meta-analysis
-------------------------------------

After a comprehensive literature search applying our inclusion criteria, 7 relevant studies including 4780 patients and 10 028 controls were identified in the final analysis. One study reported 2 case-control studies and 1 study reported 5 case-control studies. Therefore, a total of 12 studies were included in this meta-analysis. There was only 1 study with Asians, while the rest of the studies used Caucasians. Five case-control studies reported the adjusted results. The main study characteristics are summarized in [Table 1](#t1-medscimonit-20-2250){ref-type="table"}.

Quantitative synthesis
----------------------

Because of the rarity of the UBQ-8i polymorphism in the Chinese population, the study with Asians was not included in the quantitative synthesis. [Table 2](#t2-medscimonit-20-2250){ref-type="table"} lists the main results of the meta-analysis. The CC+CT genotypes of UBQ-8i was significantly associated with an increased AD risk (OR=1.15; 95%CI 1.05--1.25; *P*=0.002; [Figure 1](#f1-medscimonit-20-2250){ref-type="fig"}). The combination of adjusted ORs also found UBQ-8i polymorphism was significantly associated with AD risk (OR=1.15; 95%CI 1.02--1.30; *P*=0.02). When stratified by *APOE* ɛ4 status, *APOE* ɛ4 carriers with CC+CT genotypes had a statistically significant increased AD risk (OR=1.28; 95%CI 1.05--1.56; *P*=0.01). In addition, *APOE* non-ɛ4 carriers with CC+CT genotypes also showed an increased AD risk (OR=1.25; 95%CI 1.04--1.50; *P*=0.02). In the subgroup analysis according to age, UBQ-8i polymorphism was significantly associated with LOAD risk (OR=1.17; 95%CI 1.05--1.31; *P*=0.005), but not with EOAD risk (OR=1.12; 95%CI 0.95--1.31; *P*=0.17).

The influence analysis showed that no particular study affected the overall significance of the pooled estimates. After removing each study and recalculating the ORs, overall estimates, as well as their significance, remained nearly unchanged (data not shown). As shown in [Figure 2](#f2-medscimonit-20-2250){ref-type="fig"}, significant associations were evident with each addition of more data over time.

The shape of the funnel plot did not display any evidence of apparent asymmetry ([Figure 3](#f3-medscimonit-20-2250){ref-type="fig"}). Furthermore, the test also showed no evidence of substantial publication bias (*P*=0.336 for the Egger test).

Discussion
==========

To our knowledge, our meta-analysis of 12 case-control studies, with a total of 4780 cases and 10 028 controls, is the most comprehensive assessment of the association between UBQ-8i polymorphism and AD. Our meta-analysis indicated that UBQ-8i CC+CT genotypes carriers had a significantly increased AD risk than the TT genotype carriers. *APOE* ɛ4 carriers showed increased AD risk in previous studies \[[@b23-medscimonit-20-2250],[@b24-medscimonit-20-2250]\]. Despite the clear significance of the *APOE* ɛ4 allele with regards to risk of AD development, only about 30--40% of patients carry this allele. Therefore, other genetic risk factors have been suspected of influencing the incidence of AD. Thus, it was interesting to investigate the interactions between *APOE* ɛ4 allele and UBQ-8i polymorphisms. In the subgroup analysis by *APOE* ɛ4 status, an increased AD risk was observed in both *APOE* ɛ4 carriers and *APOE* non-ɛ4 carriers. Actually, when we limited the meta-analysis to studies that controlled for *APOE* ɛ4 status, a significant association between UBQ-8i polymorphism and AD risk was found (OR=1.16; 95%CI 1.01--1.33; *P*=0.03). This result indicates that the role of UBQ-8i polymorphism was not selective by *APOE* ɛ4 status. No significant statistical interaction was observed between the *APOE* ɛ4 allele and UBQ-8i polymorphism by previous studies. It is possible that studies with small sample sizes may have had insufficient statistical power to detect a slight effect. The subgroup analysis based on age found that this polymorphism showed increased LOAD risk, but not EOAD risk. The lack of an observed association may be due to the limited number of studies included in this meta-analysis.

UBQLN1 protein function could be modified by UBQ-8i polymorphism, which generates an alternative splicing variant \[[@b25-medscimonit-20-2250]\]. UBQ-8i is close to exon 8, 70 bp downstream of its 3′splice site. Exon 8 is absent in an alternative, in-frame transcript, denoted as transcript variant 2 (TV2). Bertram et al. assessed whether the UBQ-8i C allele affects the splicing of this exon in the *UBQLN1* message in the brain \[[@b25-medscimonit-20-2250]\]. They measured the relative abundance of the TV2 and TV1 in RNA extracts from brain tissue of 25 patients with neuropathologically confirmed AD and 17 age-matched controls. They found that TV1 levels were generally 10-fold higher than those of TV2 \[[@b25-medscimonit-20-2250]\]. In addition, the variant UBQ-8i C allele harbors a deletion of the exon 8, which eliminates a central region of the protein containing Sti1-like repeats involved in protein binding and dimerization \[[@b26-medscimonit-20-2250]\]. Therefore, UBQ-8i C allele might alter the monomer/dimer ratio of UBQLN1, thereby changing its binding capacities. In *Drosophila*, expression of human UBQ-8i C allele leads to more severe degeneration than the comparable expression of the human wild-type ubiquilin \[[@b27-medscimonit-20-2250]\]. Thus, the change originated by the UBQ-8i C allele may be a risk factor for the development of AD.

The present meta-analysis should be interpreted with caution, and several limitations merit consideration. First, due to lack of the original data of the eligible studies, we could not perform other subgroup analyses based on factors such as sex and smoking. Second, the number of published studies was not sufficient for a comprehensive analysis, particularly for Asians and Africans. However, our meta-analysis also had some merits. First, when the adjusted ORs were combined, the result was still positive. Second, there was low heterogeneity in this meta-analysis.

Conclusions
===========

The results of this meta-analysis suggest that the UBQ-8i polymorphism may be associated with AD development. Further studies with larger sample sizes are needed to further assess the presence of an association.
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###### 

Characteristics of the case-control studies included in meta-analysis.

  First author    Year   Ethnicity   Age of patients   Sex    Case (n)   Control (n)   Adjustment
  --------------- ------ ----------- ----------------- ------ ---------- ------------- ---------------------------
  Bensemain       2006   Caucasian   72.4              Both   613        653           Yes, age and sex
  Brouwers 1      2006   Caucasian   63.7              Both   182        183           Yes, age, sex, and *APOE*
  Brouwers 2      2006   Caucasian   57.5              Both   110        280           Yes, age, sex, and *APOE*
  Kamboh          2006   Caucasian   77.7              Both   928        797           Yes, age, sex, and *APOE*
  Smemo 1         2006   Caucasian   NR                Both   160        112           No
  Smemo 2         2006   Caucasian   NR                Both   196        116           No
  Smemo 3         2006   Caucasian   76.2              Both   376        353           No
  Smemo 4         2006   Caucasian   77                Both   633        731           No
  Smemo 5         2006   Caucasian   87                Both   179        330           No
  Arias-Vasquez   2007   Caucasian   62                Both   549        5728          Yes, age, sex, and *APOE*
  Golan           2008   Caucasian   76.1              Both   407        407           No
  Chuo            2011   Asian       77.9              Both   100        100           No
  Martín          2012   Caucasian   72                Both   347        238           No

NR -- not reported.

###### 

Meta-analysis for the association of UBQ-8i polymorphism with AD risk.

                           No. of studies   OR (95% CI)         *P* value   *I^2^* (%)   *P*~heterogeneity~
  ------------------------ ---------------- ------------------- ----------- ------------ --------------------
  Overall                  12               1.15 (1.05--1.25)   0.002       0            0.58
  Adjusted                 5                1.15 (1.12--1.30)   0.02        0            0.83
  *APOE* ɛ4 carriers       8                1.28 (1.05--1.56)   0.01        4            0.40
  *APOE* non-ɛ4 carriers   8                1.25 (1.04--1.50)   0.02        0            0.85
  EOAD                     3                1.12 (0.95--1.31)   0.17        0            0.77
  LOAD                     7                1.17 (1.05--1.31)   0.005       15           0.32

EOAD -- early-onset Alzheimer's disease; LOAD -- late-onset Alzheimer's disease.
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